A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.

Tanyifor M Tohnya; Sylvia S W Ng; William L Dahut; John J Wright; Philip M Arlen; James L Gulley; Catherine Parker; Jerome Zeldis; William D Figg

doi:10.3816/cgc.2004.n.006

A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.

Identifier:nobleid.org/w1/20260515/1ABDF8F0

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1ABDF8F0.svg?ark=w1%2F20260515%2F1ABDF8F0)](https://nobleid.org/work/w1/20260515/1ABDF8F0)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.

Identifier:nobleid.org/w1/20260515/1ABDF8F0

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1ABDF8F0.svg?ark=w1%2F20260515%2F1ABDF8F0)](https://nobleid.org/work/w1/20260515/1ABDF8F0)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work